Journal
JOURNAL OF THORACIC ONCOLOGY
Volume 3, Issue 2, Pages 107-110Publisher
ELSEVIER SCIENCE INC
DOI: 10.1097/JTO.0b013e3181630ece
Keywords
EGFR TK inhibitor; G-protein coupled receptors; inflammation; cyclooxygenase-2; PGE2; epithelial to mesenchymal transition; drug resistance; NSCLC
Categories
Funding
- NCI NIH HHS [K23 CA131577, 5 K12 CA076095] Funding Source: Medline
- PHS HHS [P50 90388] Funding Source: Medline
Ask authors/readers for more resources
Inflammation is an important contributor to lung tumor development and progression. In addition, inflammatory signaling may promote epithelial to mesenchymal transition, development of aggressive metastatic tumor phenotypes, and play a role in resistance to targeted therapies. New insights in inflammatory signaling have led to the evaluation of combination therapies that target these specific pathways. In addition to developing the optimal combination of targeted agents, biomarker-based selection of patients who will likely benefit will be critical to the success of this strategy. Here we focus on the potential contribution of inflammatory mediator-induced resistance to epidermal growth factor receptor tyrosine kinase inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available